Charles River Laboratories | CRL - Ebit

Aktienkurs
169.80
Täglich Wechseln
2.06 1.23%
Monatlich
2.36%
Jährlich
48.09%
Q2 Prognose
179.83




Ebit Veränderung Datum
Agilent USD 353M 90M 2025-12
Align Technology USD 224.71M 40.06M 2025-12
Bio-Rad Laboratories USD -418.8M 845.4M 2025-09
Bruker USD 76.3M 7.6M 2025-12
Cardinal Health USD 763M 9M 2025-12
Charles River Laboratories USD 75.82M 57.98M 2025-12
Cigna USD 2.58B 220M 2025-09
Concord Medical Services Hldg CNY -144.65M 69.38M 2025-06
CVS Health USD 2.11B 836M 2025-12
Danaher USD 1.34B 158M 2026-03
Dentsply International USD 538M 26M 2025-12
Elevance Health USD -5.81B 6.39B 2026-03
Galapagos EUR 780.56M 822.23M 2025-12
Humana USD -808M 1.21B 2025-12
Illumina USD 256M 6M 2025-12
Incyte USD 383.88M 47.44M 2025-12
Intrexon USD -26.3M 2.91M 2024-06
IQVIA Holdings USD 2.68B 2.1B 2025-12
Laboratory Of America USD 382M 11M 2025-12
Lonza CHF 673M 54M 2025-06
McKesson USD 1.66B 159M 2025-12
Merck EUR 474M 738M 2025-12
Mettler Toledo International USD 351.93M 57.73M 2025-12
Novartis USD 4.06B 530M 2025-12
Pfizer USD 4.65B 71M 2025-12
Quest Diagnostics USD 399M 13M 2026-03
Revvity USD 145.83M 47.49M 2025-12
Thermo Fisher Scientific USD 1.91B 389M 2026-03
United Therapeutics USD -14.6M 403.9M 2025-12
UnitedHealth USD 9.04B 5.78B 2026-03
Veradigm USD -45.47M 70.47M 2022-12
Waters USD 270.52M 78.4M 2025-12
West Pharmaceutical Services USD 177.1M 14.6M 2026-03